Defence Therapeutics Inc. | WebDisclosure

Switch to English

8610	Sociétés
141705	Mots-clés
77618	Articles
75737	Communiqués

Accueil
Sociétés
Defence Therapeutics Inc.

COMMUNIQUÉ DE PRESSE

publié le 17/06/2024 à 08:00, il y a 9 mois 24 jours

DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
Defence Therapeutics Inc.'s Chief Scientific Officer Dr. Moutih Rafei discusses the ACCUM platform for cancer treatments on Money Talk Radio with Ellis Martin

Defence Therapeutics Inc. Cancer Treatments ACCUM Platform Dr. Moutih Rafei Money Talk Radio
BRÈVE

publiée le 10/06/2024 à 08:05, il y a 10 mois 1 jour

Defence Therapeutics participera au congrès annuel 2024 du SNMMI à Toronto

Thérapeutique De Défense SNMMI AccuTRIC™ Médecine Nucléaire Imagerie Moléculaire
BRÈVE

publiée le 10/06/2024 à 08:05, il y a 10 mois 1 jour

Defence Therapeutics to Attend 2024 SNMMI Annual Meeting in Toronto

Defence Therapeutics Nuclear Medicine SNMMI AccuTRIC™ Molecular Imaging
COMMUNIQUÉ DE PRESSE

publié le 10/06/2024 à 08:00, il y a 10 mois 1 jour

DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
Defence Therapeutics Inc. to participate in the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024, presenting their novel Radio-Immuno-Conjugate (RIC) for cancer treatment

Cancer Treatment Defence Therapeutics Inc. Molecular Imaging Society Of Nuclear Medicine Radio-Immuno-Conjugate
BRÈVE

publiée le 06/06/2024 à 08:05, il y a 10 mois 5 jours

L'étude AccuTOX de Defense Therapeutics publiée dans le Journal of Translational Medicine

Immunothérapie Essais Cliniques Thérapeutique De Défense AccuTOX Anti-cancer
BRÈVE

publiée le 06/06/2024 à 08:05, il y a 10 mois 5 jours

Defence Therapeutics' AccuTOX Study Published in Journal of Translational Medicine

Clinical Trials Immunotherapy Defence Therapeutics AccuTOX Anti-cancer
COMMUNIQUÉ DE PRESSE

publié le 06/06/2024 à 08:00, il y a 10 mois 5 jours

DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Defence Therapeutics Inc.'s AccuTOX published in the prestigious Journal of Translational Medicine along with preclinical data on AccuTOX as an anti-cancer molecule. Study highlights AccuTOX's superior therapeutic properties and versatility for different cancer treatments

Preclinical Data Defence Therapeutics Inc. AccuTOX Journal Of Translational Medicine Anti-cancer Molecule
BRÈVE

publiée le 14/05/2024 à 08:05, il y a 10 mois 28 jours

Defence Therapeutics étend son portefeuille de brevets à l'échelle mondiale

Thérapeutique De Défense Délivrance De Brevet Innovation Dans Les Soins De Santé Vaccin Immuno-oncologique Système De Délivrance De Médicaments
BRÈVE

publiée le 14/05/2024 à 08:05, il y a 10 mois 28 jours

Defence Therapeutics Expands Patent Portfolio Globally

Defence Therapeutics Patent Issuance Drug Delivery System Innovation In Healthcare Immune-Oncology Vaccine
COMMUNIQUÉ DE PRESSE

publié le 14/05/2024 à 08:00, il y a 10 mois 28 jours

DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Defence Therapeutics strengthens and expands global patent protection on key technologies, including vaccine enhancer platform and ADC platform technology. The new patents and allowances showcase the company's commitment to innovation in biopharmaceuticals

Biopharmaceuticals Defence Therapeutics Patent Protection Vaccine Enhancer ADC Platform Technology

Les Echos

Publié le 11/04/2025 à 18:30, il y a 1 heure 31 minutes

Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Publié le 11/04/2025 à 18:30, il y a 1 heure 31 minutes

Reclassement d'actions au sein du concert familial Feuillet sans incidence sur le contrôle de la société
Publié le 11/04/2025 à 18:00, il y a 2 heures 1 minute

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2025
Publié le 11/04/2025 à 18:00, il y a 2 heures 1 minute

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Publié le 11/04/2025 à 17:50, il y a 2 heures 10 minutes

Mise à disposition du Rapport Financier Annuel 2024

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 11/04/2025 à 18:45, il y a 1 heure 16 minutes

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Preside
Publié le 11/04/2025 à 15:00, il y a 5 heures 1 minute

Medicure Announces Further Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of West Olympia Pharmacy
Publié le 11/04/2025 à 15:00, il y a 5 heures 1 minute

Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Publié le 11/04/2025 à 14:30, il y a 5 heures 31 minutes

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Publié le 11/04/2025 à 14:00, il y a 6 heures 1 minute

Greta Van Susteren Signs Multi-Year Renewal with Newsmax

Voir tout ACCESSWIRE

EQS Group

Publié le 11/04/2025 à 18:40, il y a 1 heure 21 minutes

AGM 2025 - Bossard Holding AG Press Release
Publié le 11/04/2025 à 18:38, il y a 1 heure 23 minutes

Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 11/04/2025 à 18:23, il y a 1 heure 38 minutes

EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Publié le 11/04/2025 à 18:10, il y a 1 heure 50 minutes

Kaufman & Broad SA: 2025, 1ST QUARTER RESULTS
Publié le 11/04/2025 à 18:10, il y a 1 heure 50 minutes

Kaufman & Broad SA: RESULTATS DU 1ER TRIMESTRE 2025